Protalix Biotherapeutics, Inc. Announces New Data On ELELYSO™ (Taliglucerase Alfa) And Oral GCD To Be Presented At The European Working Group On Gaucher Disease 2014 11th Meeting

CARMIEL, Israel, June 23, 2014 (GLOBE NEWSWIRE) -- Protalix BioTherapeutics, Inc. (NYSE-MKT:PLX) (TASE:PLX), announced today that new clinical data on ELELYSO™ and oral glucocerebrosidase (GCD), or oral GCD (PRX-112), will be presented at the European Working Group on Gaucher Disease 2014 11th Meeting being held June 25-28 in Haifa, Israel, at the Dan Carmel Hotel.

Help employers find you! Check out all the jobs and post your resume.